Here are four things to know.
1. Merck will eliminate three U.S. sales teams that promote drugs for primary care, disease-focused endocrinology and hospital chronic care.
2. The drugmaker will develop a new chronic care sales team in the U.S., creating about 960 jobs. The team will focus on selling products with more growth potential, such as the diabetes drug Januvia and the sleep medication Belsomra.
3. The reorganization represents Merck’s efforts “to better support changes in our business in the United States,” company spokeswoman Claire Gillespie told Reuters via email.
4. Merck said none of the eliminated jobs will be moved outside the country, according to the report.
More articles on supply chain:
Analysis: Biosimilar drugs could cut US healthcare spending by $54B
Health apps should be held to high regulatory scrutiny, researchers say
FDA: 50 medical devices at risk of shortages after Hurricane Maria
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
